{"entity":{"id":"nct06644781","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","aka":["IDeate-Esophageal01"],"tldr":"A phase 3 trial of Ifinatamab deruxtecan and Docetaxel in oesophageal cancer, run by Daiichi Sankyo, now recruiting.","summary":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) is a phase 3 interventional study registered as NCT06644781 by Daiichi Sankyo, with 510 participants planned, started 2025-03-27 and due to reach its primary completion in 2028-06-01. Interventions recorded: Ifinatamab deruxtecan, Docetaxel, Paclitaxel and Irinotecan hydrochloride (HCl).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06644781","url":"https://clinicaltrials.gov/study/NCT06644781"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["esophageal","oesophageal-squamous-cell-carcinoma"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["ifinatamab-deruxtecan","docetaxel"],"companies":["daiichi-sankyo","merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06644781","phase":"3","setting":"A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","sponsor":"Daiichi Sankyo","participation":[{"nct":"NCT06644781","source":"https://clinicaltrials.gov/study/NCT06644781","fetchedAt":"2026-10-07T16:54:53.335Z","studySha256":"9817eb7e73367a081ad6a4132c61d638c10a691ceea5d70fd3e83e3a6720d4bf","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-04","leadSponsor":"Daiichi Sankyo","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":510,"enrolmentType":"ESTIMATED","siteCount":132,"recruitingSiteCount":131,"countries":["Belgium","China","Denmark","France","Germany","Italy","Japan","Netherlands","Norway","Poland","Romania","South Korea","Spain","Sweden","Taiwan","United Kingdom","United States"]}],"started":"2025-03-27","startedType":"actual","enrolled":510,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06644781/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}